Go back
“At ARCHIMED, we don’t just invest from a distance. We roll up our sleeves with the companies, sometimes stepping into leadership roles directly through secondments and being truly hands-on when needed. This is how we deeply understand the business and the people behind it, build trust with management and the team, and create real, lasting value across our companies.”
Ludovic Alonzi joined ARCHIMED in 2016 and was appointed as Partner in 2025.
Ludovic brings nine years of experience in M&A advisory, gained at Marceau Finance and later at Alira Health, where he specialized in small and mid-cap healthcare transactions across Europe.
At ARCHIMED, Ludovic has developed deep expertise in the Life Sciences sector, notably contributing as a Board member to the growth and strategic development of companies such as Polyplus, Clean Biologics, and Xpress Biologics. In 2023, he further expanded his operational leadership by completing a secondment at Stragen, a generics pharmaceutical company, where he successfully led the group’s reorganization as acting CEO.
PORTFOLIO COMPANIES
